NASDAQ:ITOS

iTeos Therapeutics (ITOS) Stock Price, News & Analysis

$10.79
+0.23 (+2.18%)
(As of 04/22/2024 ET)
Today's Range
$10.46
$11.15
50-Day Range
$9.89
$13.64
52-Week Range
$8.20
$18.24
Volume
182,392 shs
Average Volume
307,337 shs
Market Capitalization
$386.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33

iTeos Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
181.1% Upside
$30.33 Price Target
Short Interest
Bearish
7.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($4.76) to ($6.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

734th out of 910 stocks

Biological Products, Except Diagnostic Industry

126th out of 154 stocks

ITOS stock logo

About iTeos Therapeutics Stock (NASDAQ:ITOS)

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

ITOS Stock Price History

ITOS Stock News Headlines

Iteos Therapeutics Inc (ITOS)
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
ITOS Oct 2024 17.000 call
ITOS Oct 2024 12.000 call
ITOS Mar 2024 4.000 put
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
ITOS Mar 2024 11.000 call
iTeos Therapeutics (NASDAQ: ITOS)
See More Headlines
Receive ITOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/23/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ITOS
Fax
N/A
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.33
High Stock Price Target
$44.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+181.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,640,000.00
Pretax Margin
-865.66%

Debt

Sales & Book Value

Annual Sales
$12.60 million
Book Value
$16.08 per share

Miscellaneous

Free Float
32,187,000
Market Cap
$386.71 million
Optionable
Optionable
Beta
1.19
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

ITOS Stock Analysis - Frequently Asked Questions

Should I buy or sell iTeos Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iTeos Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITOS shares.
View ITOS analyst ratings
or view top-rated stocks.

What is iTeos Therapeutics' stock price target for 2024?

3 brokers have issued 12-month target prices for iTeos Therapeutics' stock. Their ITOS share price targets range from $18.00 to $44.00. On average, they expect the company's share price to reach $30.33 in the next year. This suggests a possible upside of 181.1% from the stock's current price.
View analysts price targets for ITOS
or view top-rated stocks among Wall Street analysts.

How have ITOS shares performed in 2024?

iTeos Therapeutics' stock was trading at $10.95 at the start of the year. Since then, ITOS shares have decreased by 1.5% and is now trading at $10.79.
View the best growth stocks for 2024 here
.

When is iTeos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ITOS earnings forecast
.

How were iTeos Therapeutics' earnings last quarter?

iTeos Therapeutics, Inc. (NASDAQ:ITOS) announced its earnings results on Wednesday, March, 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.18.

What ETFs hold iTeos Therapeutics' stock?

ETFs with the largest weight of iTeos Therapeutics (NASDAQ:ITOS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of iTeos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iTeos Therapeutics investors own include Advanced Micro Devices (AMD), GW Pharmaceuticals (GWPH), Trevena (TRVN), Blink Charging (BLNK), Chegg (CHGG), Centene (CNC), Datadog (DDOG), Global Blood Therapeutics (GBT) and Genocea Biosciences (GNCA).

When did iTeos Therapeutics IPO?

iTeos Therapeutics (ITOS) raised $151 million in an initial public offering on Friday, July 24th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are iTeos Therapeutics' major shareholders?

iTeos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.08%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Aaron I Davis, Ansbert Gadicke, Bioventures 2014 LP Mpm, Bioventures 2018 LP Mpm, Boxer Capital, Llc, David Hallal, Detlev Biniszkiewicz, Joanne Jenkins Lager, Les B Korsh, Matthew Gall, Michel Detheux and Yvonne Mcgrath.
View institutional ownership trends
.

How do I buy shares of iTeos Therapeutics?

Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITOS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners